After the announcement, IART shares have fallen 0.2%, closing at $13.49 in yesterday's after-market trading session. On a promising note, the latest development is expected to boost the company's Codman Specialty Surgical (CSS) segment, which benefited from the recently closed acquisition of Acclarent. The acquisition positioned Integra as a leader in the ENT segment, expanding addressable markets and providing immediate scale and accretive growth to the CSS portfolio. We expect the market sentiment surroun ...